Six British bulldogs that struggled to breathe through their compressed airways showed measurable improvement after receiving an experimental injection called Snoretox-1, according to a pilot study published in The Veterinary Journal in early 2026. The results are preliminary, but they point toward something many owners of flat-faced dogs have been waiting for: a non-surgical option for a condition that affects the majority of brachycephalic breeds.
Brachycephalic obstructive airway syndrome, or BOAS, is the medical term for the chronic breathing difficulty caused by the shortened skulls that define breeds like bulldogs, pugs and French bulldogs. Research published in PubMed Central describes how the compacted bone structure crowds soft tissue into the airway, leading to noisy breathing, exercise intolerance, overheating and, in severe cases, life-threatening airway collapse. Studies suggest that more than half of bulldogs show signs of the condition. Until now, the primary interventions have been weight management, lifestyle adjustments and surgery to widen the nostrils or trim the soft palate.
What the pilot study found
The six bulldogs in the trial had moderate-to-significant BOAS, graded 2 to 3 on a standard clinical scale. Each dog received targeted bilateral injections of Snoretox-1 into the rostral geniohyoid muscle, a small muscle that helps pull the base of the tongue forward and open the upper airway. After treatment, the researchers reported clinically significant improvement on the Respiratory Functional Grading scale, a scoring system veterinarians use to assess observable breathing quality at rest and during exercise.
According to the study’s description on ScienceDirect, Snoretox-1 is classified as a targeted neuromuscular stimulant. It contains a modified form of tetanus toxin paired with a decoy molecule. While “tetanus toxin” sounds alarming, the concept borrows from an established area of pharmacology: just as botulinum toxin (Botox) is used therapeutically to relax muscles, tetanus toxin can be engineered to increase muscle tone in a controlled way. In this case, the goal is to stiffen the airway-opening muscles so they resist collapse during breathing. The researchers reported that the effect lasted weeks to months in the dogs they followed.
Why a non-surgical option matters
BOAS surgery can be effective, but it is invasive, requires general anesthesia in dogs that are already compromised, and carries risks including swelling, regurgitation and the need for repeat procedures. A separate randomized controlled trial indexed on PubMed found that applying a lignocaine and phenylephrine spray before BOAS surgery reduced postoperative regurgitation, underscoring that even routine surgical care for these dogs still involves managing significant complications.
Flat-faced breeds are also enormously popular. French bulldogs have topped registration lists in the United States and the United Kingdom in recent years, and British bulldogs and pugs remain perennial favorites. A research summary on EurekAlert! tied to a PLOS ONE study highlighted which brachycephalic breeds face the greatest breathing risk, reinforcing that the pool of dogs that could potentially benefit from a less invasive treatment is large.
For many owners, the cost and recovery time of surgery are barriers. An injection that could be administered during a standard veterinary visit and repeated as needed would represent a fundamentally different care model, one closer to managing a chronic condition than attempting a one-time surgical fix.
What researchers still need to prove
The pilot study’s biggest limitation is its size. Six dogs from a single breed is enough to justify further research but far too few to draw broad conclusions. Several critical questions remain unanswered:
- Other breeds: Pugs, French bulldogs and Shih Tzus all develop BOAS, but their airway anatomy differs from that of British bulldogs. Whether Snoretox-1 works the same way across breeds has not been tested in published data.
- Severity range: The trial included only dogs graded 2 to 3. Dogs with mild BOAS (grade 1) or the most severe cases (grade 3 trending toward collapse) were not represented.
- Long-term safety: The researchers observed benefits lasting weeks to months, but there is no published data on what happens after repeated injections over a dog’s lifetime, whether the effect diminishes, or whether chronic exposure to the modified toxin causes tissue changes.
- Head-to-head comparisons: No trial has yet compared Snoretox-1 directly with surgery on outcomes like exercise tolerance, quality of life or long-term survival.
- Regulatory status: The study does not indicate whether Snoretox-1 has been submitted for approval by veterinary regulatory bodies such as the FDA’s Center for Veterinary Medicine or the European Medicines Agency. Owners cannot currently access the treatment outside of research settings based on available information.
Putting the findings in perspective
The strongest piece of evidence behind Snoretox-1 is the peer-reviewed pilot study in The Veterinary Journal. Peer review and a clearly described methodology give it more weight than press coverage alone, but a pilot study is, by design, a starting point. It demonstrates feasibility, not definitive proof.
Coverage from outlets like Phys.org has helped bring attention to the research, though the most reliable details about how the injection works and what it achieved still come from the primary paper.
The broader body of BOAS research, including the evidence-based review on PubMed Central, makes clear that breathing difficulty in flat-faced dogs is fundamentally a structural problem rooted in skull shape. No injection can reshape bone. What Snoretox-1 appears to do is compensate for some of the soft-tissue consequences of that structure by strengthening the muscles that hold the airway open.
What owners should know right now
For people living with a bulldog, pug or other brachycephalic dog that snores, overheats or tires quickly on walks, the Snoretox-1 research is worth watching but not yet something to act on. The injection is not commercially available as of May 2026, and no veterinary regulatory body has publicly cleared it for clinical use.
In the meantime, the established recommendations still apply: keep flat-faced dogs at a healthy weight, avoid exercise in heat, use harnesses instead of collars to reduce pressure on the airway, and consult a veterinarian experienced with brachycephalic breeds about whether surgery is appropriate. If larger trials confirm what this small pilot study suggests, Snoretox-1 could eventually become one more tool in that toolkit, not a replacement for careful breeding and responsible ownership, but a way to help dogs that are already here breathe a little easier.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
